Scilex Holding Co
Closed (deSPAC)Profile in progress
- What it is
- Holding Company Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain
- What it’s doing now
- Merging with Scilex Holding Co (VCKA) — closed (despac).
- What you should know
- Data is still being assembled for this company — what is shown below is everything we have verified so far.
The business, per its filings
SEC primaryHolding Company Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex is uncompromising in its focus to become the global pain management leader committed to social, environmental, economic, and ethical principles to responsibly develop pharmaceutical products to maximize quality of life. Results from the Phase III Pivotal Trial C.L.E.A.R Program for SEMDEXA TM , its novel, non-opioid product for the treatment of lumbosacral radicular pain (sciatica), were announced in March 2022. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with moderate to severe pain. Scilex launched its first commercial product in October 2018, in-licensed a commercial product in June 2022, and is developing its late-stage pipeline, which includes a pivotal Phase 3 candidate and one Phase 2 and one Phase 1 candidate. Its commercial product, ZTlido ® (lidocaine topical system) 1.8%, or ZTlido ® , is a prescription lidocaine topical product approved by the U.S. Food and Drug Administration for the relief of pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. Scilex in-licensed the exclusive right to commercialize Gloperba ® (colchicine USP) oral solution, an FDA-approved prophylactic treatment for painful gout flares in adults, in the U.S. Scilex is planning to commercialize Gloperba ® in 2023 and is well-positioned to market and distribute the product. Scilexs three product candidates are SP-102 (injectable dexamethasone sodium phosphate viscous
What the company says about itself
Web research — not auditedScilex Holding Company is an innovative revenue-generating company focused on acquiring, developing, and commercializing non-opioid pain management products for acute and chronic pain. It aims to become the global pain management leader through proprietary delivery technologies and pharmaceuticals that maximize quality of life.
- Markets:
- Pharmaceuticals | Pain Management
- Products:
- ZTLIDO | ELYXYB | GLOPERBA | SEMDEXA | SP-103 | SP-104
[WEB-INTEL 2026-08-26] 3 finding(s) · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Scilex Holding Company Announces Signing of Binding Term Sheet for Proposed $100 Million Strategic Investment from iHolding Group" [https://www.globenewswire.com/news-release/2026/07/06/3322261/0/en/scilex-holding-company-announces-signing-of-binding-term-sheet-for-proposed-100-million-strategic-investment-from-iholding-group-llp.html] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Scilex Holding Company Announces 5-Year Term of $100 Million Financing with Royalty-Based Payments and Potential Strategic Transactions with iHolding Group" [https://firstwordpharma.com/story/5866026] · web source asserts a FILING-ONLY figure (deadline / trust / status / floor / price) and it was NOT stored: "Issuing approximately 6.67 million new shares would increase Scilex's outstanding share count. However: the company would receive $100 million" [https://www.reddit.com/r/BANDOFBROTHERSOFSRNE/comments/1uot466/investor_buys_100ml_of_sclx_stock_at_15share_or/]
Source: https://www.scilexholding.com/ · captured Aug 26, 2026 · marketing claims are reported as claims, never merged into the filed figures above.
The deal it’s entering
Scilex Holding Co is merging with Scilex Holding Co (VCKA) currently marked Closed (deSPAC).
| Headline equity value | — |
Structure per SEC accession(s) 0001104659-22-074469. How to read these numbers: headline vs effective valuation · what a definitive agreement commits
What exactly is being valued, and at what
Common questions
Is Scilex Holding Co going public?
Scilex Holding Co has an approved merger with the SPAC Scilex Holding Co (VCKA). Deal status: Closed (deSPAC).
Does Scilex Holding Co have revenue?
The filings we've parsed don't state a usable revenue figure yet; this profile is updated as new documents land.
Educational content, not investment advice.